Abstract
Rapid clonal proliferation and accumulation of immature lymphocytes characterize acute lymphoblastic leukemia (ALL). Substantial progress in the cure rate achieved with chemotherapy (CT) has occurred in children with ALL, but results in adults remain poor (1). Significant progress in understanding the biology and heterogeneity of this disease has not yet led to significant improvement in outcome (2). This chapter critically reviews present treatment results in ALL, and presents a rationale for an aggressive treatment strategy.
Keywords
- Acute Lymphoblastic Leukemia
- Acute Leukemia
- Unrelated Donor
- Allogeneic Bone Marrow Transplantation
- Autologous Bone Marrow Transplantation
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Copelan EA and McGuire EA. Biology and treatment of ALL in adults, Blood, 85 (1995) 1151–68.
Proctor SJ. Acute lymphoblastic leukaemia in adults: the case for a strategic shift in study approach, Br. J. Hematol., 88 (1994) 229–233.
Forman SJ. Allogeneic transplantation for acute lymphoblastic leukemia in adults. In Thomas ED, Blume KG, and Forman SJ (eds.), Hematopoietic Cell Transplantation, 2nd ed. Blackwell, Malden, MA, 1998, pp. 849–858.
Loeffler H, Kayser W, Schmitz N Morphological and cytochemical classification of adult acute leukemias in two multicenter studies in the Federal Republic of Germany, Haemotol. Blood Transfusion, 30 (1987) 21.
Pui, C-H, Behm FG, and Crist WM. Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia, Blood, 82 (1993) 343–362.
Crist W, Pullen J, Boyett J Acute lymphoid leukemia in adolescents: clinical and biologic features predict a poor prognosis: a Pediatric Oncology Group Study, J. Clin. Oncol., 6 (1988) 34–43.
Kersey J, Nesbit M, Hallgren H, Sabad A, Yunis E, and Gajl-Peczalska K. Evidence of origin of certain childhood acute lymphoblastic leukemia and lymphoma in thymus-derived lymphocytes, Cancer, 36 (1975) 1348–1352.
Reinherz EL, Kung PC, Goldstein G, Levey RH, and Schlossman SF. Discrete stages of human intrathymic differentiation. Analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage, Proc. Natl. Acad. Sci. USA, 77 (1980) 1588–1592.
Theil E, Kranz BK, Raghavachar A Prethymic phenotype and genotype of pre-T (CD7VER-) cell leukemia and its clinical significance within acute lymphoblastic leukemia, Blood, 73 (1989) 1247.
Boucheix C, David B, Sebban C Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia, Blood, 84 (1994) 1603–1612.
Bloomfield CD, Seeker-Walker LM, Goldman AI Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia, Cancer Genet. Cytogenet., 40 (1989) 171–185.
Faderl S, Kantarjian HM, Talpaz M, and Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia, Blood, 91 (1998) 3995–4019.
Bloomfield CD, Lindquist LL, Arthur D Chromosome abnormalities and their clinical significance in acute lymphoblastic leukemia (for the Third International Workshop on Chromosomes in Leukemia), Cancer Res., 43 (1986) 868.
Bloomfield CD, Goldman AI, Alimena G Chromosome abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia, Blood, 67 (1986) 415–420.
Williams PL, Ramondi SC, Rivera G Presence of clonal abnormalities in virtually all cases of acute lymphoblastic leukemia, N. Engl. J. Med., 313 (1985) 640.
Rabbitts TH. Translocations, mastergenes and difference between origins of acute and chronic leukemias, Cell, 67 (1991) 641–644.
Nichols J and Nimer SD. Transcription factors, translocations, and leukemia, Blood,80 (1992) 29532963.
Bloomfield CD, Lindquist LL, Brunning RD, Yunis JJ, and Coccia PF Philadelphia chromosome in acute leukemia, Virchows Arch. (B) 29 (1978) 81–91.
Arthur DC, Bloomfield CD, Lindquist LL, and Nesbit ME Jr. Translocation 4; 11 in acute lymphoblastic leukemia: clinical characteristics and prognostic significance, Blood, 59 (1982) 96–99.
Levin MD, Michael PM, Garson OM, Tiedemann K, and Firkin FC. Clinical pathological characteristics of acute lymphoblastic leukemia with the 4:11 chromosome translocation, Pathology, 16 (1984) 63–66.
Pui C-H. Acute leukemias with the t(4;11)(g21’3), Leukemia Lymphoma, 7 (1992) 173–179.
Michael PM, Levin MD, and Garson OM. Translocation 1:19: a new cytogenetic abnormality in acute lymphoblastic leukemia, Cancer Genet. Cytogenet., 12 (1984) 333–341.
Secker-Walker LM, Craig JM, Hawkins JM, and Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, bcr break-point, and prognostic significance, Leukemia, 5 (1991) 196–199.
Lestingi TM and Hooberman AL. Philadelphia positive acute lymphoblastic leukemia, Hematol. Oncol. Clin. North Am., 7 (1993) 161–175.
Bloomfield CD, Secker-Walker LM, Goldman AI Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia, Cancer Gene Cytogenet., 40 (1989) 171–185.
Westbrook Ca, Hooberman L, Spino C,Clinical significance of the bcr-abl fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762), Blood, 80 (1992) 2983–2990.
Tuszynski A, Dhut S, Young BD Detection and significance of bcr-abl mRNA transcripts and fusion proteins in Philadelphia-positive adult acute lymphoblastic leukemia, Leukemia,7 (1993) 15041508.
Janssen JWG, Ludwig W-D, Sterry W, and Bartram CR. SIL-Tall deletion in T-cell acute lymphoblastic leukemia, Leukemia, 8 (1993) 1204–1210.
Bash RO, Hall S, Timmons CF, Crist WM, Amylon M, Graham Smith R, and Baer R. Does activation of the TALI gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A Pediatric Oncology Group Study, Blood, 86 (1995) 666–676.
Rubnitz JE, Downing JR, Pui C-H TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance, J. Clin. Oncol., 15 (1997) 1150–1157.
Shurtleff SA, Bujis A, Behm FG TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup with an excellent prognosis, Leukemia, 9 (1995) 1985–1989.
Haidar MA, Cao X-B, Manshouri T pl61NK4A and p15INx4B gene deletions in primary leukemias, Blood, 86 (1995) 311–315.
Quesnel B, Preudhomme C, Philippe N,p16 gene homozygous deletions in acute lymphoblastic leukemia, Blood, 85 (1995) 657–663.
Hammond D, Sather H, Nesbit M,Analysis of prognostic factors in acute lymphoblastic leukemia, Med. Pediatr. Oncol., 14 (1986) 124–134.
Sather FIN. Age at diagnosis in childhood acute lymphoblastic leukemia, Med. Pediatr. Oncol., 14 (1986) 166–172.
Leumert JT, Burns CP, Wiltse CG, Armitage JO, and Clark WA. Prognostic information of pretreatment characteristics in adult acute lymphoblastic leukemia, Blood, 56 (1980) 510.
Hoelzer D. Change in treatment strategies for adult acute lymphoblastic leukemia (ALL) according to prognostic factors and minimal residual disease, Bone Marrow Transplant., 6 (S1) (1990) 66–70.
Hoelzer D. Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. In Bloomfield CD, Herzig GP (eds.), Hematology/Oncology Clinics of North America, W.B. Saunders, Philadelphia, 1993, pp. 139–160.
Hoelzer D, Thiel E, Löffler H Intensified chemotherapy and mediastinal irradiation in adult T-cell acute lymphoblastic leukemia. In Gale RP, Hoelzer D (eds.), Acute Lymphoblastic Leukemia, Liss, New York, 1990, pp. 221–229.
Schwenn MR, Blattner SR, Lynch E, and Weinstein HJ. HiC-COM: A 2-month intensive chemotherapy regimen for children with stage HI and IV Burkitt’s lymphoma and B-cell acute lymphoblastic leukemia, J. Clin. Oncol., 9 (1991) 133–138.
Reiter A, Schrappe M, Ludwig W-D Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group, Blood, 80 (1992) 2471–2478.
Pees HW, Radtke H, Schwamborn J, and Graf N. The BFM-protocol for HIV-negative Burkitt’ s lymphomas and L3 ALL in adult patients: a high chance for cure, Ann. Hematol., 65 (1992) 201–205.
Barrett AJ, Horowitz MM, Gale RP Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival, Blood, 74 (1989) 862–871.
Bortin MM, Truitt RL, Rimm AA, and Bach FH. Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity, Nature, 281 (1979) 490–491.
Weisdorf DJ, Nesbit ME, Ramsay NCK Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease, J. Clin. Oncol., 5 (1987) 1348–1355.
Doney K, Fisher LD, Appelbaum FR Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versushost disease, relapse, and relapse-free survival, Bone Marrow Transplant., 7 (1991) 453–459.
Horowitz MM, Gale RP, Sondel PM Graft-versus-leukemia reactions after bone marrow transplantation, Blood, 75 (1990) 555–562.
Blume KG, Forman SJ, Krance RA, Henke M, Findley DO, and Hill LR. Bone marrow transplantation for acuate leukemia, Hematol. Blood Transfusion, 29 (1985) 39–41.
Gratwhol A, Hermans J, Zwaan F, for the EBMT. Bone marrow transplantation for ALL in Europe. In Gale RP and Hoelzer D (eds.), Acute Lymphoblastic Leukemia, Liss, New York, 1990, pp. 271.
Herzig RH, Barrett AJ, Gluckman E,Bone marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission, Lancet, (1987) 786–789.
Butturini A and Gale RP. Chemotherapy versus transplantation in acute leukaemia, Br. J. Hematol., 72 (1989) 1–8.
Forman S, Schmidt G, Nademanee A Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia, J. Clin. Oncol., 9 (1991) 1570–1574.
Biggs JC, Horowitz MM, Gale RP Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy, Blood, 80 (1992) 1090–1093.
Frassoni F, Lobopin M, Gluckman E Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time: a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT), Bone Marrow Transplant., 17 (1996) 13–18.
Kernan MA, Bartsch G, Ash RC,Retrospective analysis of 462 unrelated marrow transplants facilitated by the National Marrow Donor Program for treatment of acquired and congenital disorders of the lymphohematopoietic system and congenital metabolic disorders, N. Engl. J. Med.,328 (1993) 592-.
Beatty PG, Hansen JA, Longton GM Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies, Transplantation, 51 (1991) 443–447.
Champlin R and Gale RP. Acute lymphoblastic leukemia: recent advances in biology and therapy, Blood, 73 (1989) 2051–2066.
Forman Si, O’Donnell MR, Nademanee AP Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, Blood, 70 (1987) 587–588.
Barrett AJ, Horowitz MM, Ash RC Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia, Blood, 79 (1992) 3067–3070.
Copelan EA, Kapoor N, Murcek M, Theil K, and Tutschka PJ. Marrow transplantation following busulfan and cyclophosphamide as treatment for translocation (4;11) acute leukemia, Br. J. Haematol., 70 (1988) 127–128.
Horowitz MM, Messerer D, Hoelzer D Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission, Ann. Intern. Med., 115 (1991) 13–18.
Zhang Mi, Hoelzer D, Horowitz MM,Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee, Ann. Intern. Med., 123 (1995) 428–431.
Slovak ML, Kopecky KJ, Wolman SR Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: a Southwest Oncology Group Study (SWOG-8612), Leukemia Res., 19 (1995) 381–388.
Oh H, Gale RP, Mang M-J Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. Bone Marrow Transplant., 22 (1998) 253–257.
Blume KG, Forman Si, Snyder DS,Allogeneic bone marrow transplantation for acute lymphoblastic leukemia during first complete remission, Transplantation, 43 (1987) 389–392.
Vernant JT, Marit G, Maraninchi D Allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia in first complete remission, J. Clin. Oncol., 6 (1988) 227–231.
Blaise D, Gespard MH, Stoppa AM Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission, Bone Marrow Transplant., 5 (1990) 7–12.
Forman SJ. Role of allogeneic bone marrow transplantation in the treatment of high-risk acute lymphocytic leukemia in adults, Leukemia, 11 (1997) S18–519.
Sebban C, Lepage E, Vernant JP Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study, J. Clin. Oncol., 12 (1994) 2580–2587.
Vey N, Blaise D, Stoppa AM Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission, Bone Marrow Transplant., 14 (1994) 383–388.
Attal M, Blaise D, Marit G Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation, Blood, 86 (1995) 1619–1628.
Klingemann HG, Storb R, Fefer A Bone marrow transplantation in patients aged 45 years and older, Blood, 67 (1986) 770–776.
Copelan EA, Kapoor N, Berliner M, and Tutschka PJ. Bone marrow transplantation without total-body irradiation in patients aged 40 and older, Transplantation, 48 (1989) 65–68.
Appelbaum FR, Clift R, Radich J, Anasetti C, and Buckner CD. Bone marrow transplantation for chronic myelogenous leukemia, Semin. Oncol., 22 (1995) 405–411.
Copelan E, Penza S, Theil K Allogeneic marrow transplantation with BuCy2 in patients with chronic myelogenous leukemia, Blood, 92S1 (1998) 285a.
Fiere D, Lepage E, Sebban C,for the French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy, J. Clin. Oncol., 11 (1993) 1990–2001.
Vey N, Stoppa AM, Faucher C Bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in first complete remission (CR!): Long-term outcome of 88 patients treated in a single institution. Proceedings of the IBMTR-ABMTR ASBMT Tandem Meetings, Keystone, CO, February 28—March 6, 1999, p. 35. Abstract C-1.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Penza, S.L., Copelan, E.A. (2000). Should All Adult Patients with Acute Lymphoblastic Leukemia in First Remission Undergo Allogeneic Bone Marrow Transplantation?. In: Bolwell, B.J. (eds) Current Controversies in Bone Marrow Transplantation. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-657-7_7
Download citation
DOI: https://doi.org/10.1007/978-1-59259-657-7_7
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9812-7
Online ISBN: 978-1-59259-657-7
eBook Packages: Springer Book Archive